AbCellera (ABCL) announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application for ABCL575, an investigational antibody antagonist targeting OX40 ligand that is being developed for the treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evaluate the safety and pharmacokinetics of ABCL575 administered subcutaneously in healthy participants.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera price target lowered to $10 from $28 at Truist
- AbCellera Biologics Receives Health Canada Approval for Trial
- AbCellera receives NOL from Health Canada for ABCL635 clinical trial application
- AbCellera Wins Patent Appeal Against Bruker
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge